Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
暂无分享,去创建一个
D. Franchimont | S. Vermeire | A. Gils | B. Verstockt | S. Tops | W. van Moerkercke | C. Liefferinckx
暂无分享,去创建一个
D. Franchimont | S. Vermeire | A. Gils | B. Verstockt | S. Tops | W. van Moerkercke | C. Liefferinckx